From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q3 2018 call → NOWe need to determine if management describes a recent transition to being an approved/specified/listed/etc. choice inside buyers' systems, such that future business can arrive without discrete selling events, and that this is new enough that most volume is ahead. Looking at the transcript: The discussion about Avanti Communications Group. Peter Reed says: "We’ve had a number of positive developments from the company over the past six months since Kyle Whitehill joined the company as its new CEO. Despite the long sales cycle in the telecom space, Kyle has signed three large potentially highly profitable and long-term new contracts. We believe that each of these contracts would be amongst the largest in the company’s history. First, in June, Avanti singed a $10 million two-year contract with Viasat for its HYLAS 4 satellite. Next, in August 2018, Avanti signed a seven-year Master Distribution Agreement for HYLAS 4 with COMSAT, providing Avanti access to the U.S. government. Lastly, in September, Avanti announced its seven-year, wholesale capacity lease agreement for $84 million with a major player in the satellite space. With these contract wins in place, we would expect to see significant revenue growth from Avanti going forward. That, coupled with its largely fixed operating costs could ultimately translate into significant and recurring cash flow." This describes specific contracts, not a general approved supplier status. The Master Distribution Agreement with COMSAT provides access to U.S. government, but that is a distribution agreement, not necessarily a listing in a procurement system. The contracts are specific wins, not a gateway that makes future orders automatic. Also, the revenue growth is expected, but not described as "most volume is ahead" in the sense of a new access status. The contracts are discrete wins, not a systemic inclusion. So this does not match the phenomenon. Other parts: No mention of being added to formularies, approved lists, etc. The company is a BDC, so not typical. The question is about the company's own products. The Avanti contracts are for satellite capacity, but they are specific deals. No indication that these are part of a routine pathway where future orders come without selling. So answer NO. Also, the question asks if management conveys that the status is recent and flow is only beginning.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.